Asia and Global Semiconductor and Tech Research

Andrew Lu

Equity Bottom-Up

Taigen Biopharmaceuticals / Equity Bottom-Up

<h2>Summary</h2><ul>
<li>
<strong>What's new? </strong>Taigen and HEC Pharm announced a new joint venture.  HEC Pharm agrees Taigen to use its developed new drug Furaprevir (TG-2349) at RMB$335mn or NT$1.56bn investment value to take 49% of the new company.</li>
<li>
<strong>What is Furaprevir? </strong>On August 18, 2016, Taigen received a clinical trial authorization for Class 1.1 new drug from China Food and Drug Administration (CFDA) for Furaprevir. Furaprevir is an investigational HCV NS3 protease inhibitor discovered and developed by TaiGen for the…</li>
</ul>

Summary

What's new? Taigen and HEC Pharm announced a new joint venture.  HEC Pharm agrees Taigen to use its developed new drug Furaprevir (TG-2349) at RMB$335mn or NT$1.56bn investment value to take 49% of the new company.

What is Furaprevir? On August 18, 2016, Taigen received a clinical trial authorization for Class 1.1 new drug from China Food and Drug Administration (CFDA) for Furaprevir. Furaprevir is an investigational HCV NS3 protease inhibitor discovered and developed by TaiGen for the…


TaiGen Sold Its Furaprevir for 25x of Market Capital

Taiwan

TaiGen Biopharmaceuticals Holdings Limited is a research-based pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer research and diabetes-related complications.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Taigen Biopharmaceuticals (4157 TT)

TaiGen Sold Its Furaprevir for 25x of Market Capital

Summary What's new? Taigen and HEC Pharm announced a new joint venture. HEC Pharm agrees Taigen to use its developed new drug Furaprevir...

Andrew Lu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)